These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30915633)

  • 21. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
    Jackson G; Taylor P; Smith GM; Marcus R; Smith A; Chu P; Littlewood TJ; Duncombe A; Hutchinson M; Mehta AB; Johnson SA; Carey P; MacKie MJ; Ganly PS; Turner GE; Deane M; Schey S; Brookes J; Tollerfield SM; Wilson MP
    Br J Haematol; 2001 Jan; 112(1):127-37. PubMed ID: 11167793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
    Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
    Hatsumi N; Miyawaki S; Yamauchi T; Takeshita A; Komatsu N; Usui N; Arai Y; Ishida F; Morii T; Kano Y; Ogura M; Machida S; Nishii K; Honda S; Ohnishi K; Naoe T;
    Int J Hematol; 2019 Apr; 109(4):418-425. PubMed ID: 30725360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
    Kim H; Lee JH; Joo YD; Bae SH; Lee JH; Kim DY; Lee WS; Ryoo HM; Jo JC; Choi Y; Lee KH;
    Eur J Haematol; 2016 Feb; 96(2):188-97. PubMed ID: 25891993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
    Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
    Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
    BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
    J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias.
    Farooq MU; Mushtaq F; Farooq A; Khan DH; Mir MA
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1191-1193. PubMed ID: 30887181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
    Westhus J; Noppeney R; Dührsen U; Hanoun M
    Leuk Lymphoma; 2019 Apr; 60(4):1014-1022. PubMed ID: 30277107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia.
    Westhus J; Noppeney R; Schmitz C; Flasshove M; Dührsen U; Hanoun M
    Acta Haematol; 2020; 143(5):438-445. PubMed ID: 31655809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
    Burnett AK; Russell NH; Hills RK; Hunter AE; Kjeldsen L; Yin J; Gibson BE; Wheatley K; Milligan D
    J Clin Oncol; 2013 Sep; 31(27):3360-8. PubMed ID: 23940227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
    Ossenkoppele GJ; Graveland WJ; Sonneveld P; Daenen SM; Biesma DH; Verdonck LF; Schaafsma MR; Westveer PH; Peters GJ; Noordhuis P; Muus P; Selleslag D; van der Holt B; Delforge M; Löwenberg B; Verhoef GE;
    Blood; 2004 Apr; 103(8):2908-13. PubMed ID: 15070662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
    Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.
    Kim H; Lee JH; Joo YD; Bae SH; Lee JH; Kim DY; Lee WS; Ryoo HM; Jo JC; Park JH; Lee KH
    Acta Haematol; 2014; 132(1):87-96. PubMed ID: 24513865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
    Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
    J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).
    Ferrara F; Palmieri S; Pocali B; Pollio F; Viola A; Annunziata S; Sebastio L; Schiavone EM; Mele G; Gianfaldoni G; Leoni F
    Eur J Haematol; 2002 Apr; 68(4):203-9. PubMed ID: 12071935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
    Yu W; Mao L; Qian J; Qian W; Meng H; Mai W; Tong H; Tong Y; Jin J
    Ann Hematol; 2013 Aug; 92(8):1091-100. PubMed ID: 23595277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.